In today's episode, we dive into the Biden-Harris administration's landmark legislation to cap insulin prices at $35 per month for seniors on Medicare, aimed at alleviating the financial strain of diabetes.
We contrast this comprehensive and mandatory cap with the limited and voluntary measures enacted during the Trump administration.
We discuss the broader impacts of this policy, including preventing insulin rationing and ensuring that seniors don't have to choose between their health and other essential needs.
The episode also addresses common concerns about the cap stifling pharmaceutical innovation and provides listeners with actionable steps to ensure their voices are heard in the upcoming election.
Here is a fact-checking link you can use to help convince people you're speaking with: https://www.kff.org/health-costs/poll-finding/public-opinion-on-prescription-drugs-and-their-prices/.
In today's episode, we dive into the Biden-Harris administration's landmark legislation to cap insulin prices at $35 per month for seniors on Medicare, aimed at alleviating the financial strain of diabetes.
We contrast this comprehensive and mandatory cap with the limited and voluntary measures enacted during the Trump administration.
We discuss the broader impacts of this policy, including preventing insulin rationing and ensuring that seniors don't have to choose between their health and other essential needs.
The episode also addresses common concerns about the cap stifling pharmaceutical innovation and provides listeners with actionable steps to ensure their voices are heard in the upcoming election.
Here is a fact-checking link you can use to help convince people you're speaking with: https://www.kff.org/health-costs/poll-finding/public-opinion-on-prescription-drugs-and-their-prices/.